Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2, double blind, placebo controlled, dose-ranging study in subjects with postherpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability, and pharmacokinetics of four doses of TAK-583, compared with placebo.

Next Previous
X
Search
Trial Profile

A phase 2, double blind, placebo controlled, dose-ranging study in subjects with postherpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability, and pharmacokinetics of four doses of TAK-583, compared with placebo.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Aug 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAK 583 (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center

    • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2005-005863-26).
    • 09 Jun 2010 Actual patient number (399) added as reported by ClinicalTrials.gov.
    • 18 Dec 2008 Planned number of patients changed from 400 to 399 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top